RU2015137158A3 - - Google Patents

Download PDF

Info

Publication number
RU2015137158A3
RU2015137158A3 RU2015137158A RU2015137158A RU2015137158A3 RU 2015137158 A3 RU2015137158 A3 RU 2015137158A3 RU 2015137158 A RU2015137158 A RU 2015137158A RU 2015137158 A RU2015137158 A RU 2015137158A RU 2015137158 A3 RU2015137158 A3 RU 2015137158A3
Authority
RU
Russia
Application number
RU2015137158A
Other languages
Russian (ru)
Other versions
RU2707126C2 (ru
RU2015137158A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015137158A publication Critical patent/RU2015137158A/ru
Publication of RU2015137158A3 publication Critical patent/RU2015137158A3/ru
Application granted granted Critical
Publication of RU2707126C2 publication Critical patent/RU2707126C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00041Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
RU2015137158A 2009-12-07 2010-12-07 МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ RU2707126C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26709809P 2009-12-07 2009-12-07
US61/267,098 2009-12-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012128586/10A Division RU2564125C2 (ru) 2009-12-07 2010-12-07 Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019132267A Division RU2804336C2 (ru) 2019-10-11 МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ

Publications (3)

Publication Number Publication Date
RU2015137158A RU2015137158A (ru) 2018-12-25
RU2015137158A3 true RU2015137158A3 (enExample) 2018-12-25
RU2707126C2 RU2707126C2 (ru) 2019-11-22

Family

ID=43597993

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2012128586/10A RU2564125C2 (ru) 2009-12-07 2010-12-07 Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
RU2015137158A RU2707126C2 (ru) 2009-12-07 2010-12-07 МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2, hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2012128586/10A RU2564125C2 (ru) 2009-12-07 2010-12-07 Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени

Country Status (12)

Country Link
US (3) US9549968B2 (enExample)
EP (3) EP2990798B1 (enExample)
JP (5) JP5913120B2 (enExample)
KR (2) KR101842076B1 (enExample)
CN (1) CN102770764B (enExample)
AU (1) AU2010329995B2 (enExample)
BR (1) BR112012013662B1 (enExample)
CA (1) CA2779562C (enExample)
DK (2) DK2990798T3 (enExample)
RU (2) RU2564125C2 (enExample)
SG (1) SG10201408073XA (enExample)
WO (1) WO2011069992A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3230907B2 (ja) 1993-09-03 2001-11-19 川崎製鉄株式会社 生産性および黒色化に優れた黒色化処理鋼板の製造方法
US9549968B2 (en) * 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
WO2013113851A1 (en) 2012-01-31 2013-08-08 Technische Universitaet Muenchen Muteins of a1m lipocalin and method of production therefor
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
WO2014081980A2 (en) * 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN113621050A (zh) 2014-05-22 2021-11-09 皮里斯制药有限公司 新型特异性结合多肽及其用途
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3064507A1 (en) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
US11261221B2 (en) * 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107787327B (zh) * 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白
FI3298030T3 (fi) 2015-05-18 2023-02-22 Pieris Pharmaceuticals Gmbh Syöpää ehkäisevä fuusiopolypeptidi
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
SG11201803732PA (en) * 2015-11-30 2018-06-28 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018015380A1 (en) 2016-07-18 2018-01-25 Philippe Ulsemer Natural microorganisms which are naturally capable of binding toxins and/or toxin receptors
GB201615254D0 (en) * 2016-09-08 2016-11-23 Ge Healthcare Bio Sciences Ab Novel Ligand and use thereof
CN107403074B (zh) * 2017-06-09 2018-05-29 天津市湖滨盘古基因科学发展有限公司 一种突变蛋白的检测方法及装置
EP3715370A1 (en) * 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
US6020163A (en) 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20140080177A1 (en) 1997-09-26 2014-03-20 Pieris Ag Anticalins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CA2343917A1 (en) 1998-10-19 2000-04-27 Ariad Gene Therapeutics, Inc. Materials and methods involving conditional retention domains
AU781292B2 (en) * 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
AU2007280398B2 (en) * 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CA2702590A1 (en) * 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
US9549968B2 (en) * 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
DK2640740T3 (en) * 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
CA2891557A1 (en) * 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
AR103714A1 (es) 2015-02-18 2017-05-31 Sanofi Sa Proteínas específicas para pioverdina y pioquelina
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3(gpc3)具有亲和力的人脂质运载蛋白2的突变蛋白
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
WO2011069992A3 (en) 2011-08-11
BR112012013662A2 (pt) 2020-11-03
JP2021006024A (ja) 2021-01-21
EP2510357A2 (en) 2012-10-17
US20200308237A1 (en) 2020-10-01
JP7482544B2 (ja) 2024-05-14
JP2016105709A (ja) 2016-06-16
EP3660510A2 (en) 2020-06-03
RU2707126C2 (ru) 2019-11-22
RU2015137158A (ru) 2018-12-25
KR20180031081A (ko) 2018-03-27
JP5913120B2 (ja) 2016-05-11
CA2779562A1 (en) 2011-06-16
KR20120117815A (ko) 2012-10-24
BR112012013662B1 (pt) 2022-08-02
JP2018148914A (ja) 2018-09-27
EP2990798A1 (en) 2016-03-02
EP2510357B1 (en) 2016-03-30
EP3660510A3 (en) 2020-07-08
EP2990798B1 (en) 2019-09-25
AU2010329995B2 (en) 2015-09-17
KR101974044B1 (ko) 2019-04-30
SG10201408073XA (en) 2015-01-29
US11827681B2 (en) 2023-11-28
US20130079286A1 (en) 2013-03-28
US10618941B2 (en) 2020-04-14
RU2012128586A (ru) 2014-01-20
CN102770764A (zh) 2012-11-07
WO2011069992A2 (en) 2011-06-16
CA2779562C (en) 2019-12-31
KR101842076B1 (ko) 2018-03-27
DK2510357T3 (en) 2016-07-18
JP2013512683A (ja) 2013-04-18
US9549968B2 (en) 2017-01-24
JP6346159B2 (ja) 2018-06-20
JP2022160410A (ja) 2022-10-19
AU2010329995A1 (en) 2012-05-10
RU2564125C2 (ru) 2015-09-27
DK2990798T3 (da) 2019-12-02
CN102770764B (zh) 2016-04-20
US20170114109A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
BE2015C040I2 (enExample)
BR112012008195A2 (enExample)
BR112012003062A2 (enExample)
BR112012008267A2 (enExample)
BR112012012396A2 (enExample)
BR122021004633A2 (enExample)
BR112012000665A2 (enExample)
BR112012012487A2 (enExample)
BR112012003080A2 (enExample)
BR122017024704A2 (enExample)
BR112012003853A2 (enExample)
BR112012012080A2 (enExample)
BR112012009797A2 (enExample)
BR112012009446A2 (enExample)
BR112012009703A2 (enExample)
BR112012010357A2 (enExample)
BR112012007656A2 (enExample)
BR112012001263A2 (enExample)
RU2015137158A3 (enExample)
BR112012014856A2 (enExample)
BR112012000159A2 (enExample)
BR112012007654A2 (enExample)
BR112012005951A2 (enExample)
BR112012007672A2 (enExample)
BR112012000255A2 (enExample)